Maja D. Andersen

Arhus, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphoma.

Lymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphoma.

Journal: Scientific reports
Published: April 28, 2025

Tumor-associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma.

Tumor-associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma.

Journal: The journal of pathology. Clinical research
Published: March 27, 2025

Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity.

Proteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity.

Journal: Leukemia & lymphoma
Published: December 03, 2024

Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era.

Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era.

Journal: Cancers
Published: September 18, 2024

Differential tumor protein expression at follicular lymphoma diagnosis reveals dysregulation of key molecular pathways associated with histological transformation.

Differential tumor protein expression at follicular lymphoma diagnosis reveals dysregulation of key molecular pathways associated with histological transformation.

Journal: Scientific reports
Published: September 18, 2024

Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement.

Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement.

Journal: European journal of haematology
Published: July 08, 2024

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort.

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort.

Journal: Blood cancer journal
Published: May 14, 2024

Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma.

Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma.

Journal: Blood advances
Published: July 25, 2023

IDO1 Protein Is Expressed in Diagnostic Biopsies from Both Follicular and Transformed Follicular Patients.

IDO1 Protein Is Expressed in Diagnostic Biopsies from Both Follicular and Transformed Follicular Patients.

Journal: International journal of molecular sciences
Published: March 10, 2023

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma - A study from the Danish Lymphoma Registry.

Journal: British journal of haematology
Published: December 20, 2021

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling.

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling.

Journal: Cancers
Published: November 22, 2021

Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy.

Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy.

Journal: British journal of haematology
Published: December 21, 2018
Showing 1-12 of 16

Last Updated: 09/26/2026